Harvard Bioscience, Inc. (NASDAQ:HBIO) CEO Jeffrey Duchemin sold 87,022 shares of the business’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $4.53, for a total transaction of $394,209.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Harvard Bioscience, Inc. (NASDAQ:HBIO) traded up $0.20 on Monday, hitting $4.80. 144,131 shares of the stock traded hands, compared to its average volume of 167,103. The company has a market cap of $160.45, a P/E ratio of -240.00 and a beta of 1.32. Harvard Bioscience, Inc. has a one year low of $2.25 and a one year high of $5.20. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.40 and a quick ratio of 1.87.
Harvard Bioscience (NASDAQ:HBIO) last released its earnings results on Thursday, March 1st. The medical instruments supplier reported $0.05 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.05. The company had revenue of $27.46 million during the quarter, compared to the consensus estimate of $26.60 million. Harvard Bioscience had a negative net margin of 0.85% and a positive return on equity of 2.38%. sell-side analysts expect that Harvard Bioscience, Inc. will post 0.11 earnings per share for the current year.
HBIO has been the subject of several research analyst reports. Benchmark boosted their target price on shares of Harvard Bioscience from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, January 23rd. Janney Montgomery Scott boosted their target price on shares of Harvard Bioscience from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Finally, Zacks Investment Research raised shares of Harvard Bioscience from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research report on Thursday. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $7.75.
TRADEMARK VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/03/12/insider-selling-harvard-bioscience-inc-hbio-ceo-sells-87022-shares-of-stock.html.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.